Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Other Accumulated Expenses (2017 - 2025)

Tvardi Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $321000.0 for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 3912.5% to $321000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $321000.0, a 3912.5% increase, with the full-year FY2025 number at $321000.0, up 3912.5% from a year prior.
  • Other Accumulated Expenses hit $321000.0 in Q4 2025 for Tvardi Therapeutics, down from $452000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for TVRD hit a ceiling of $452000.0 in Q3 2025 and a floor of $8000.0 in Q4 2024.